中文Recently, BioGeometry, a digital biology pioneer, and Sino Biological, a leading recombinant protein production company, have reached a strategic cooperation agreement. This collaboration combines BioGeometry’s generative AI protein design and optimization platform with Sino Biological’s protein expression and other wet-lab platforms. Building on the success of previous projects, the two parties aim to further deepen their cooperation and jointly explore high-value market opportunities.
Currently, deep learning, especially large-scale generative AI models, is ushering in a new era of digitalized, intelligent biomanufacturing. Following the breakthrough in protein structure prediction achieved by AlphaFold2, this year’s AlphaFold3, based on diffusion generative models, can predict the structures of all biomolecules, garnering industry-wide attention and enthusiasm. What’s more, generative AI models like RFDiffusion have been proven to increase success rates of protein design by several or even hundreds of times compared to traditional rational design methods.
BioGeometry has always focused on building a generative AI protein design platform to empower the biopharmaceutical and biomanufacturing fields. Its core team are pioneers in generative AI for molecular generation, who, in 2021, first applied diffusion models to the generation of three-dimensional molecular structures. Their key paper, GeoDiff, was among the top 50 most cited papers in the AI field in 2022.
In June this year, BioGeometry released GeoFlow, a generative protein foundation model that can be used for both structure prediction and protein design. Based on BioGeometry’s proprietary geometric deep learning architecture and the cutting-edge flow matching generative model, GeoFlow has achieved performance on par with AlphaFold3 in the task of antigen-antibody complex structure prediction, making it the first protein design model to reach such docking accuracy. Currently, GeoFlow is freely available for non-commercial public use. It is also integrated into BioGeometry’s AI-driven computing platform, GeoBiologics, enabling users to obtain better molecules with fewer wet experiments, thus refreshing the protein design and optimization experience.
Sino Biological specializes in providing comprehensive, high-quality recombinant proteins and antibodies for life science research and innovative drug development. The company has established a one-stop CRO technical service platform covering gene cloning, protein expression, antibody development and production, and quality control research. It provides preclinical scale production services for monoclonal antibody candidate drugs to pharmaceutical or biotechnology companies. With the capability to produce purified monoclonal antibodies from gene sequence to 1-30 grams in just a few weeks, Sino Biological a globally leading company in antibody production speed. The company has a comprehensive antibody discovery platform, incorporating hybridoma technology, phage display technology, single B cell antibody screening technology, and supports high-throughput production and comprehensive screening and efficacy evaluation platforms, enabling rapid and efficient screening of functional antibodies.
BioGeometry and Sino Biological complement each other in generative AI and wet lab experiments, providing AI-driven scientific research tools and CRO services for domestic and international customers. The BioGeometry protein computing platform, based on GeoFlow, is more efficient and of higher precision than traditional rational design methods. Combined with Sino Biological’s efficient and reliable protein expression and wet lab platform, we can now predict and optimize multiple properties in a single project by update AI models with high throughput experimental data, helping our customers complete design and validation swiftly to gain a competitive edge. So far, we have successfully implemented several CRO and scientific research reagent development projects, covering high-value macromolecules such as nanobodies and biological reagent enzymes. Looking ahead, we will further explore the deep application of AI in protein research and development, jointly creating an innovative model of AI-empowered protein R&D, accelerating the intelligent era of protein research and development, and making significant contributions to global biopharmaceutical scientific research, disease treatment, and high-quality sustainable development.
About BioGeometry
BioGeometry is a digital biology pioneer that specializes in applying generative AI to protein design. Founded in 2022 by Prof. Jian Tang and with Turing Award laureate Yoshua Bengio serving as the chief scientific advisor, BioGeometry enjoys some of the greatest minds and talents in the field of AI4Protein. The team were among the first to apply diffusion generative models to biomolecular structure modeling. We also developed GeoFlow, a cutting-edge protein foundation model that excels in both protein design and structure modeling. Our AI-driven biologics design platform (GeoBiologics) and high-throughput wet-lab validation platform form a closed “design-build-test-learn” loop, enabling multi-objective, highly accurate and efficient protein design and optimization for biomedicine and synthetic biology.
About Sino Biological
Sino Biological is a leading expert in protein and antibody research and production in China, focusing on providing comprehensive, high-quality recombinant proteins and antibodies for life science research and innovative drug development, as well as professional, one-stop technical services. Headquartered in Beijing, it is a national high-tech enterprise listed on the Shenzhen Stock Exchange’s ChiNext board in August 2021, with the stock code 301047. Sino Biological has built a full set of key technologies and five core technology platforms for innovative research and development of biological reagents centered on proteins and antibodies. The company currently produces and sells more than 74,000 types of stocked products, including nearly 9,000 recombinant proteins, more than 14,000 antibodies, over 50,000 genes, and a series of high-performance serum-free media products. It has established a one-stop CRO technical service platform covering gene cloning, protein expression, antibody development and production, and quality control research. The company has successfully developed high-difficulty reagents such as full-length membrane proteins, kinases, and phosphorylated antibodies, as well as several high-quality GMP-grade cytokine products. With the technical ability to independently develop more than 2,000 recombinant protein and antibody products annually, Sino Biological has built the world’s leading human cell-expressed recombinant protein biological reagent library.